Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer ascopubs.org/doi/10.1200/OP… out on Journal of Clinical Oncology Over the past decade, germline genetic testing (GGT) has become increasingly important in managing prostate cancer, especially

Major cancer breakthroughs of 2024: Leading oncologists from UCLA Health, Perlmutter Cancer Center at NYU Langone Health, Memorial Sloan Kettering Cancer Center & Cleveland Clinic highlight groundbreaking drug approvals and screening advances that are transforming patient care. Thank you to Beth Karlan, David Wise MD PhD, Jessica Geiger,

CircRNA is the most bizarre yet fascinating RNA. Our work of circRMST in prostate and lung cancer is now online at Cancer Cell. Great teamwork with Misha Beltran and Jun Qing and many others. Thanks for the support from Terry Fox Research Institute Prostate Cancer Foundation The Princess Margaret Cancer Foundation CIHR and more

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials ascopubs.org/doi/abs/10.120… This study validates a novel

What’s shaping the future of #GenitourinaryCancers? Find out April 30 in NYC at the State of the Science Summit™ with David Wise MD PhD, David H Aggen, MD PhD, Mark Stein, & Minas Economides, MD. Don't miss it! Register today: hubs.li/Q03hKl0G0 NYU Langone Health

Fascinating insights from MSK gastrointestinal medical oncologist Karuna Ganesh on the role of #Ecoli in age-dependent cell cycle entry for early onset #colorectal cancer initiation. #AACR25 AACR

Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma sciencedirect.com/science/articl… This study examined the clinical outcomes & genomic landscape of urothelial carcinoma with aberrant histology (UCAH) in a cohort

A big step forward vs cancer nature.com/articles/d4158…

Enco/cet + mFOLFOX6 is the new standard 1L for BRAF V600E mut mCRC patients ➡️ mPFS: 12.8 vs 7.1 mos ➡️ mOS: 30.3 vs 15.1 mos #ASCO25 ASCO

📢 #ASCO25 | Investigator-initiated Ph. I | Abemaciclib window of opportunity (CDK4-6 Inh) Pre-RC in MIBC – Abema before cystectomy: pCR 18.8%, downstaging 31.3%; on-target activity reduction in RB1-p, ctDNA showed tumor fraction reduction by 28.6%. Well-tolerated (G3 anemia 20%,

Breaking News: Darolutamide is now FDA-approved for mHSPC. It’s used with standard hormone therapy as part of combination treatment—the gold standard for mHSPC. Learn why this matters: pcf.org/the-new-standa…

Phase I trial combines ONC-392 with Lutetium-177 for #ProstateCancer. David Wise, MD, PhD NYU Langone Health joins Tian Zhang, MD, MHS UT Southwestern Medical Center discussing this phase I trial of ONC-392 + 177Lu-PSMA, targeting Tregs to overcome resistance after lutetium therapy. Early results: safe, no

Just announced at #ASCO25: The ArteraAI Prostate Test is now enhanced for high-risk localized prostate cancer—helping identify which patients benefit from abiraterone and who may safely avoid added toxicity, cost, and complexity: itnonline.com/content/prosta…

Exciting result! I would love to collaborate on a project looking at real world data on the use of Tarlatamab for neuroendocrine prostate cancer Prostate Cancer Foundation #prostatecancer Movember USA

Child walks again after receiving experimental treatment for rare genetic condition statnews.com/2025/07/09/nyu… Incredible study in nature from my soon to be next door lab neighbor Michael Pacold NYU Langone Health Perlmutter Cancer Center at NYU Langone Health

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to Stephen Freedland, MD neal shore & team! Earlier enza works better! Link👉 rb.gy/iyc3f2 OncoAlert UroToday.com Prostate Cancer Foundation

Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab Displays High Response Rate in Unresectable Melanoma #oncology #melanoma Janice Mehnert, MD Perlmutter Cancer Center at NYU Langone Health hubs.li/Q03xhxb50

New review in European Urology: 🌱Plant-based, Mediterranean & low-inflammatory diets are linked with lower prostate cancer progression & mortality. 🍔Western & ultra-processed diets increase risks. #ProstateCancer #Oncology #Prevention European Urology Prostate Cancer Foundation Advanced Prostate Cancer Consensus Conference

⭕️In a cohort of 86,632 adults with obesity, GLP-1 receptor agonists were linked to lower overall cancer risk. ⭕️Notably ↘️ risk: endometrial, ovarian, meningioma. ⭕️But signal for ↗️kidney cancer risk. Balance of benefit & caution. JAMA Oncology OncoAlert jamanetwork.com/journals/jamao…

What a treat to present our study in beautiful Bermuda! DAVA Oncology